Lumretuzumab

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameLumretuzumab
Drug Alias NameRG-7116RO-5479599
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonists
TargetsReceptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungBreast NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaNetherlandsDenmark +[7] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesF. Hoffmann-La Roche Ltd
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungBreast NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksWikipedia